A Phase 2a, Proof of Concept Trial, testing twice daily application of LEO 124249 ointment 30mg/g in the treatment of mild to moderate inverse psoriasis
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs LEO 124249 (Primary)
- Indications Inverse psoriasis
- Focus Proof of concept; Therapeutic Use
- Sponsors LEO Pharma
- 10 Aug 2016 Status changed from recruiting to completed.
- 15 Mar 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 03 Mar 2016 New trial record